We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Majority of EOLOA Applicants Choose Death

By HospiMedica International staff writers
Posted on 08 Jan 2018
A new study shows that three quarters of terminally ill adults in California qualified to receive End of Life Option Act (EOLOA) drugs ingest them and die.

In a new research letter, investigators at Kaiser Permanente School of Medicine (Pasadena, CA, USA) and Kaiser Permanente Southern California (Pasadena, USA) described how Kaiser Permanente dealt with the first year of implementation of EOLOA, providing outcomes and characteristics of 379 individuals who initiated the EOLOA process. More...
The most common reasons cited for pursuing EOLOA were not wanting to suffer and no longer being able to participate in activities that made life enjoyable.

Of the 379 patients initiated an inquiry through June 30, 2017, 176 were deemed eligible, with 55% of the patients suffering impairment in activities of daily living and receiving palliative care, or were staying at a hospice at the time of their inquiry. Most of the patients suffered from cancer, and in the previous 12 months had received care mainly from specialists. In all, 74% of the patients who received the EOLOA drugs ingested them and died within a median of nine days after receiving the prescription. The study research letter was published on December 26, 2017, in JAMA Internal Medicine.

“The California End of Life Option Act, which took effect on June 9, 2016, allows qualified adults diagnosed with a terminal disease to request aid-in-dying drugs from their physician,” concluded lead author Huong Nguyen, PhD, and colleagues. “Patients' end-of-life concerns appear difficult to palliate, with the most common cited reasons for pursuing EOLOA being existential suffering, inability to enjoy life, and loss of autonomy.”

California is the fifth state in the United States to enact an aid-in-dying law. To be eligible, an individual must be an adult, a California resident, have a diagnosis from a primary physician of an incurable and irreversible disease which will, within reasonable medical judgment, result in death within six months. Petitioners must be confirmed to be able to make medical decisions for themselves, voluntarily request the aid-in-dying drug without influence from others, and be able to self-administer the drug. Requests must be made solely and directly by the patient to the attending physician, and cannot be made through a power of attorney, health care agent, or any other legally recognized health care decision maker.

Related Links:
Kaiser Permanente School of Medicine
Kaiser Permanente Southern California


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.